Regeneron Q3 net income rises 33% to $1.95 billion; Q3 revenues climb 36% to $5.12 billion
- Regeneron’s third-quarter GAAP EPS rose 35% year-over-year to $18.45, while total revenues climbed 36% to $5.12 billion.
- An expanded Sanofi collaboration includes a $1 billion upfront payment and up to $7 billion in future milestones.
- The FDA cleared Pasatru in August 2026 to reduce new bone lesions and flare-ups in adults with fibrodysplasia ossificans progressiva.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300630PRIMZONEFULLFEED9856733) on October 30, 2026, and is solely responsible for the information contained therein.